Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
-
New pill targets stubborn colorectal cancer mutation
Disease control Recruiting nowThis study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC